What is the effect of pitobrutinib on liver function?

Pirtobrutinib is a highly selective, non-covalent BTK (Bruton's tyrosine kinase) inhibitor, mainly used for treatment. Bcell malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). In clinical application, this drug may have certain effects on liver function and therefore requires close monitoring.

1. Effects on liver enzyme levels: Pitobrutinib may cause increases in liver enzymes (ALT, AST), which is a common side effect of many BTK inhibitors. Although elevations in liver enzymes are mild and reversible in most cases, some patients may experience significant elevations that may even lead to liver damage. Therefore, liver function should be monitored regularly during the initial period of medication and during treatment, especially in patients with a history of liver disease.

2. Potential hepatotoxicity: Although there are currently few reports of severe liver injury caused by pitobrutinib, there have been cases of hepatotoxicity with other BTK inhibitors (such as ibrutinib). Therefore, patients who use pitobrutinib for a long time should be alert to possible liver damage, such as jaundice, fatigue, decreased appetite, or darker urine. If liver function abnormalities worsen, dose adjustment or medication suspension may be necessary.

3. Precautions for patients with liver disease: Patients with existing liver disease (such as chronic hepatitis or cirrhosis) should be particularly cautious when using pitobrutinib. These patients may be more susceptible to drug-related liver damage, so doctors may need to adjust dosage and increase monitoring.

Pitobrutinib may cause an increase in liver enzymes, and some patients may develop abnormal liver function. It is recommended to assess liver function before treatment and to monitor it regularly during treatment. If severe liver damage occurs, medication may need to be adjusted or discontinued to ensure safety.